Aziyo Biologics, Inc. (NASDAQ:AZYO) was the recipient of a large decline in short interest in the month of December. As of December 31st, there was short interest totalling 1,800 shares, a decline of 88.4% from the December 15th total of 15,500 shares. Based on an average trading volume of 16,700 shares, the short-interest ratio is currently 0.1 days. Approximately 0.1% of the shares of the company are sold short.
In related news, insider Thomas Englese purchased 4,580 shares of the company’s stock in a transaction that occurred on Tuesday, December 14th. The shares were purchased at an average price of $6.10 per share, for a total transaction of $27,938.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Highcape Capital, L.P. purchased 412,735 shares of the company’s stock in a transaction that occurred on Wednesday, December 8th. The stock was bought at an average price of $4.24 per share, for a total transaction of $1,749,996.40. The disclosure for this purchase can be found here. Insiders own 45.00% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. O Shaughnessy Asset Management LLC acquired a new stake in shares of Aziyo Biologics in the 2nd quarter worth approximately $28,000. Morgan Stanley grew its holdings in shares of Aziyo Biologics by 370.0% in the 2nd quarter. Morgan Stanley now owns 3,295 shares of the company’s stock worth $32,000 after acquiring an additional 2,594 shares during the period. Ergoteles LLC acquired a new stake in shares of Aziyo Biologics in the 2nd quarter worth approximately $96,000. Millennium Management LLC grew its holdings in Aziyo Biologics by 73.0% during the 3rd quarter. Millennium Management LLC now owns 28,550 shares of the company’s stock valued at $202,000 after buying an additional 12,047 shares during the last quarter. Finally, Birchview Capital LP acquired a new stake in Aziyo Biologics during the 2nd quarter valued at $288,000. Institutional investors and hedge funds own 80.18% of the company’s stock.
Aziyo Biologics (NASDAQ:AZYO) last issued its earnings results on Monday, November 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.19). The business had revenue of $11.49 million for the quarter, compared to analysts’ expectations of $11.54 million. Aziyo Biologics had a negative return on equity of 140.59% and a negative net margin of 43.12%. During the same period last year, the company posted ($15.79) earnings per share. On average, equities analysts forecast that Aziyo Biologics will post -1.87 earnings per share for the current fiscal year.
A number of equities analysts have recently issued reports on AZYO shares. Piper Sandler cut their target price on Aziyo Biologics from $14.00 to $11.00 and set an “overweight” rating for the company in a research note on Tuesday, November 9th. Cantor Fitzgerald reissued an “overweight” rating on shares of Aziyo Biologics in a research note on Thursday, November 11th. Finally, Zacks Investment Research raised Aziyo Biologics from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research note on Tuesday.
About Aziyo Biologics
Aziyo Biologics, Inc, a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device; and cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons.
Receive News & Ratings for Aziyo Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aziyo Biologics and related companies with MarketBeat.com's FREE daily email newsletter.